Literature DB >> 24811832

The health risk of chrysotile asbestos.

David M Bernstein1.   

Abstract

PURPOSE OF REVIEW: The word asbestos is a poorly attributed term, as it refers to two very different minerals with very different characteristics. One is the serpentine mineral of which the white asbestos, chrysotile, is the most common. The other is the amphibole asbestos, which includes the blue asbestos crocidolite and the brown asbestos amosite. Although today chrysotile is the only type used commercially, the legacy of past use of amphibole asbestos remains. This review clarifies the differences between the two mineral families referred to as asbestos and summarizes the scientific basis for understanding the important differences in the toxicology and epidemiology of these two minerals. RECENT
FINDINGS: Biopersistence and sub-chronic inhalation toxicology studies have shown that exposure to chrysotile at up to 5000 times the current threshold limit value (0.1 fibers/cm) produces no pathological response. These studies demonstrate as well that following short-term exposure the longer chrysotile fibers rapidly clear from the lung and are not observed in the pleural cavity. In contrast, short-term exposure to amphibole asbestos results quickly in the initiation of a pathological response in the lung and the pleural cavity.
SUMMARY: Significant progress has been made in understanding the factors that influence inhalation toxicology studies of fibers and epidemiological studies of workers. Evaluation of the toxicology and epidemiology studies of chrysotile indicates that it can be used safely under controlled use. In contrast, even short-term exposure to amphibole asbestos can result in disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24811832     DOI: 10.1097/MCP.0000000000000064

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  7 in total

1.  How conflicted authors undermine the World Health Organization (WHO) campaign to stop all use of asbestos: spotlight on studies showing that chrysotile is carcinogenic and facilitates other non-cancer asbestos-related diseases.

Authors:  Xaver Baur; Colin L Soskolne; Richard A Lemen; Joachim Schneider; Hans-Joachim Woitowitz; Lygia Therese Budnik
Journal:  Int J Occup Environ Health       Date:  2015-03-02

Review 2.  Recent Scientific Evidence Regarding Asbestos Use and Health Consequences of Asbestos Exposure.

Authors:  Manuela Valenzuela; Margarita Giraldo; Sonia Gallo-Murcia; Juliana Pineda; Laura Santos; Juan Pablo Ramos-Bonilla
Journal:  Curr Environ Health Rep       Date:  2016-12

3.  Scientific journals and conflict of interest disclosure: what progress has been made?

Authors:  Kathleen Ruff
Journal:  Environ Health       Date:  2015-05-30       Impact factor: 5.984

4.  Inorganic Fiber Lung Burden in Subjects with Occupational and/or Anthropogenic Environmental Asbestos Exposure in Broni (Pavia, Northern Italy): An SEM-EDS Study on Autoptic Samples.

Authors:  Silvia Damiana Visonà; Silvana Capella; Sofia Bodini; Paola Borrelli; Simona Villani; Eleonora Crespi; Andrea Frontini; Claudio Colosio; Elena Belluso
Journal:  Int J Environ Res Public Health       Date:  2021-02-19       Impact factor: 3.390

Review 5.  Asbestos-Related Disorders in Germany: Background, Politics, Incidence, Diagnostics and Compensation.

Authors:  Xaver Baur
Journal:  Int J Environ Res Public Health       Date:  2018-01-16       Impact factor: 3.390

6.  Impact of asbestos on public health: a retrospective study on a series of subjects with occupational and non-occupational exposure to asbestos during the activity of Fibronit plant (Broni, Italy).

Authors:  Silvia D Visonà; Simona Villani; Federica Manzoni; Yao Chen; Giorgio Ardissino; Francesca Russo; Matteo Moretti; Gulnaz T Javan; Antonio Osculati
Journal:  J Public Health Res       Date:  2018-12-20

7.  Ongoing downplaying of the carcinogenicity of chrysotile asbestos by vested interests.

Authors:  Xaver Baur; Arthur L Frank
Journal:  J Occup Med Toxicol       Date:  2021-02-23       Impact factor: 2.646

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.